MedTrace Logo

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

NCT05850234 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2026-05-06

No results posted yet for this study

Summary

This trial is a Phase 1b/2, open-label, multicenter study of AZD0120, a CD19/BCMA dual CAR T-cell therapy, in adult subjects with relapsed/refractory multiple myeloma.

Conditions

Interventions

BIOLOGICAL

AZD0120

AZD0120 is a BCMA/CD19 dual CAR T product under investigation for the treatment of participants with RRMM.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-20
Primary Completion
2027-08-31
Completion
2028-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05850234 on ClinicalTrials.gov